Oyster Point's Tyrvaya To Be Covered By the Largest Medicare Pharmacy Benefit Manager

Oyster Point Pharma announced that the largest Medicare Pharmacy Benefit Manager in the United States will add Tyrvaya Nasal Spray on its Medicare Part D formularies, effective September 1, 2022.

“We are excited to announce this important milestone which will further expand patient access and enable continued momentum in eye care professionals prescribing Tyrvaya,” Jeffrey Nau, PhD, MMS, president and chief executive officer of Oyster Point Pharma, said in a company news release. “In the United States, almost half of the total dry eye disease prescriptions are covered by Medicare, and we believe Tyrvaya provides a truly compelling treatment option. We are committed to growing patient access and are looking forward to continue engaging with Medicare Part D health plans.”